- Joined
- Oct 6, 2018
- Messages
- 336
- Reaction score
- 452
For people working in, with, or around nuclear radiology, I was wondering what your guys’ departmental approaches was to developing targeted radiotherapy / theranostics.
Are your departments increasingly setting aside clinic space and time? Is this related to the strength of your relationship with the heme/onc department? With theranostics becoming increasingly prevalent and lots of preclinical, and phase 1, 2, and 3 trials going on for various therapeutic radiopharmaceuticals, I was trying to get a feel for how nucs departments nationwide are preparing for this, if at all.
Are your departments increasingly setting aside clinic space and time? Is this related to the strength of your relationship with the heme/onc department? With theranostics becoming increasingly prevalent and lots of preclinical, and phase 1, 2, and 3 trials going on for various therapeutic radiopharmaceuticals, I was trying to get a feel for how nucs departments nationwide are preparing for this, if at all.
